On January 4, 2022 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, reported that company management will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 10 – 13, 2022 (Press release, Cardiff Oncology, JAN 4, 2022, View Source [SID1234598109]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the presentation can be found below.

H.C. Wainwright BioConnect Virtual Conference

Presentation Date:

Available on-demand beginning at 7:00 AM ET on Monday, January 10, 2022

A webcast of the presentation will be available on the "Events" section of the Cardiff Oncology website.